Point Biopharma Global Inc's Competitiveness
A competitive positioning analysis and financial ratio benchmarking of Point Biopharma Global Inc (PNT) against its publicly traded competitors: sales growth, net income, profitability, valuation and market share, plus each peer's market capitalization, revenue, income and employees. Free below: the top 5 peers. Subscriber access adds the full competitor list and CSV downloads.
Key Findings: Point Biopharma Global Inc vs Its Competitors
- TTM: Trailing 12-month revenue of 244M vs 57,334M combined for tracked competitors (0.4% combined share).
- Trending: Latest-quarter revenue run-rate is decelerating (-95.4% annualized vs trailing 12 months), vs decelerating (-98.9%) for its tracked peer group.
- Profitability: Its -888.0% net margin compares with -715.2% for the peer group.
- Peer revenue share: Point Biopharma Global Inc accounted for 1.8% of combined revenue among its tracked peer group.
- Peer differentiation: Revenue per employee of $2.44M compares with $0.73M for the peer group (3.4x).
Every figure above is sourced and cited in detail further down this page (Market Structure, Profitability & Cost Structure, Productivity vs Peers).
PNT Sales vs. its Competitors, Q3 2023
With a net margin of -887.97 %, Point Biopharma Global Inc reported lower profitability than its competitors (-715.16 %).
Point Biopharma Global Inc generated 1.82 % of the combined sales of its peer group.
Point Biopharma Global Inc vs. its Competitors, Q3 2023
Net margin
Revenue run-rate vs trailing 12 months
TTM net margin
TTM = trailing twelve months. Run-rate annualizes the latest quarter (×4) and compares it to TTM. In millions of $. High-Confidence Competitors are named as a competitor directly in an SEC filing; Similar-Size Competitors are the closest peers by market-cap rank within the same industry; Similar Growth & Profitability Competitors are the closest peers by combined revenue growth, operating margin and ROIC, all independent of the competitor list.
TTM revenue, latest-quarter run-rate and net income/margin benchmarked across Point Biopharma Global Inc and its 4 competitor groupings. Available under Commercial License.
| Entity | TTM Revenue | Rev Run-rate vs TTM |
|---|---|---|
| Point Biopharma Global Inc | $12,345M | +12.3% · Accelerating |
| Competitors combined | $12,345M | +12.3% · Accelerating |
| High-Confidence Competitors (2) | $12,345M | +12.3% · Accelerating |
TTM revenue, run-rate and net margin benchmarking across Point Biopharma Global Inc's competitor groups requires a Commercial License.
Point Biopharma Global Inc's Competitor Quality Breadth
Share of each group, trailing 12 months: profitable (net margin > 0), expanding (revenue growth > 0), growing faster than the industry's own median, and financially distressed (Piotroski F-Score of 2 or below).
| Entity | Profitable | Expanding | Above Industry Growth | Distressed |
|---|---|---|---|---|
| Point Biopharma Global Inc | Yes | - | - | Yes |
| Competitors combined (44) | ||||
| High-Confidence Competitors (2) | - | - | - |
Source: CSIMarket API, trailing 12 months. Altman Z-Score is not shown here: it is not populated in the underlying data for any company. Percentages are of companies in each group that report the relevant metric, not of the full group size.
PNT Stock Performance relative to its Competitors
PNT Stock Performance relative to High-Confidence Competitors
5 Best-Performing Tracked Competitors, Trailing 12 Months
| # | Competitor | TTM Share Price Return | vs U.S.A. 500 |
|---|---|---|---|
| 1 | Rallybio Corporation | 282.9% | Outperformed |
| 2 | Edgewise Therapeutics inc | 282.9% | Outperformed |
| 3 | Roivant Sciences Ltd | 282.9% | Outperformed |
| 4 | Boundless Bio Inc | 282.9% | Outperformed |
| 5 | Precigen Inc | 282.9% | Outperformed |
TTM share price return and U.S.A. 500 outperformance for Point Biopharma Global Inc's best-performing tracked competitors requires a Commercial License.
Source: CSIMarket API, trailing 12 months.
Publicly Traded Peers of Point Biopharma Global Inc
Revenue and income for trailing 12 months, in millions of $, except employees| Company | Market Cap | Revenues |
|---|---|---|
| Point Biopharma Global Inc | 1,322.07 | 243.69 |
| Novartis Ag | 287,150.40 | 56,674.00 |
| Roivant Sciences Ltd | 26,654.32 | 7.53 |
| Merus N v | 6,810.81 | 56.61 |
| Edgewise Therapeutics inc | 4,284.18 | - |
| Precigen Inc | 2,767.01 | 31.60 |
| SUBTOTAL | 337,342.78 | 57,597.04 |
Sign in to see all competitors of Point Biopharma Global Inc .
Sources: Point Biopharma Global Inc's official press releases and regulatory filings; CSIMarket.com's market research; and the financial filings and press releases of the other companies cited.
Updated on:
Focus of this report: publicly traded companies. Ten additional tables on Point Biopharma Global Inc versus competitors, including market share analysis, are in the navigation menu under Competition. To download the tables, please subscribe.
Point Biopharma Global Inc's Competitors Named by the Company
Competitive relationships identified from SEC filings and corroborating sources, each with a basis and confidence.| Competitor | Basis | Confidence |
|---|---|---|
| Qsam Biosciences Inc | Named by the company | 85% |
| Fusion Pharmaceuticals Inc | Named by the company | 85% |
Filing basis, confidence, active dates and source counts for Point Biopharma Global Inc's named competitors require a Commercial License.
Methodology: relationships are extracted from SEC filings (named-competitor disclosures) and corroborating sources. Named by the company = explicitly disclosed as a competitor; Inferred = derived from corroborating signals. Confidence reflects evidence strength.
Point Biopharma Global Inc's Business Segment Mix vs Peers
Revenue by operating segment or division, as named and reported by each company. Segment names are the filer's own and are not standardized across companies. Do not assume a same-named or similarly-named segment is defined identically between two companies. Shares are of each company's own total revenue and are not required to sum to 100% (intersegment revenue, unallocated items).| Company | Largest Segment |
|---|---|
| Precigen Inc | Reportable 100.00 % |
| Uniqure N v | Single Reportable Segment 100.00 % |
| 2seventy Bio Inc | Reportable 100.00 % |
| Cartesian Therapeutics Inc | Operating 100.00 % |
| Rallybio Corporation | Reporting 100.00 % |
Source: operating segment revenue as reported in each company's SEC filings (10-K/10-Q), via the CSIMarket API, leaf-level reportable segments only (parent roll-up segments are excluded where sub-segments are separately disclosed).
Sign in to see all peers for Point Biopharma Global Inc .
Point Biopharma Global Inc's Productivity vs Peers Comparison
Revenue and income per employee, trailing 12 months, in $; market cap in millions of $| Company | Market Cap | Revenue / Employee | Income / Employee |
|---|---|---|---|
| Point Biopharma Global Inc | 1,322 | 2,436,927 | 965,512 |
| Novartis Ag | 287,150 | 752,973 | 185,566 |
| Roivant Sciences Ltd | 26,654 | 10,043 | -552,803 |
| Merus N v | 6,811 | 539,105 | -3,629,857 |
| Edgewise Therapeutics inc | 4,284 | - | -1,350,836 |
| Precigen Inc | 2,767 | 197,469 | -1,277,613 |
| PEERS TOTAL | 336,021 | 725,891 | 135,247 |
Sign in to see all peers for Point Biopharma Global Inc .
Point Biopharma Global Inc's Profitability & Cost Structure
Trailing 12-month margins from SEC-filed financials. Operating margin is compared to the Major Pharmaceutical Preparations industry median; gross margin, EBITDA margin and capital intensity are compared to the live industry average (341 companies).| Metric | Company | Industry | Difference |
|---|---|---|---|
| Gross Margin | 100.00 % | 64.89 % (avg) | +35.1 pp |
| Operating Margin | 44.23 % | industry median | +152.1 pp |
| EBITDA Margin | 56.65 % | -7.21 % (avg) | +63.9 pp |
| Capital Intensity (Capex / Revenue) | 7.93 % | 4.92 % (avg) | +3.0 pp |
Source: CSIMarket API, trailing 12 months. SG&A and R&D as a share of revenue have limited coverage as this data is backfilled and appear only where reported. Higher capital intensity is not inherently negative; it reflects the industry's asset requirements.
Point Biopharma Global Inc's Valuation vs Competitive Position
Valuation multiples vs the Major Pharmaceutical Preparations industry average (341 companies, excluding loss-making/negative-equity outliers), alongside returns on capital for context on whether a premium or discount lines up with measurably stronger or weaker returns.| Metric | Company | Industry Average | Difference |
|---|---|---|---|
| P/E | 8.8x | 25.1x | -16.3x |
| EV / EBITDA | 4.1x | 17.3x | -13.2x |
| P/B | 2.2x | 4.5x | -2.3x |
| Return on Equity | 21.10 % | industry aggregate | 9.64 % |
| Return on Invested Capital | 11.63 % | -2.95 % (avg) | 14.58 % |
Source: CSIMarket API, trailing 12 months. A valuation premium or discount is not, by itself, a judgment of over- or under-valuation. Compare it against the return and growth context shown elsewhere on this page.
Point Biopharma Global Inc's Multi-Year Financial Trajectory
Fiscal-year revenue growth, operating margin, return on invested capital and P/E, as reported in SEC filings.| Metric | 2020 | 2021 | 2022 |
|---|---|---|---|
| Revenue Growth | - | - | - |
| Operating Margin | - | - | - |
| Return on Invested Capital | - | -15.11 % | 19.98 % |
| P/E | - | - | 7.2x |
Source: CSIMarket API, fiscal-year figures. P/E is this company's own historical ratio at each fiscal year end and can swing sharply around an earnings trough: that is real, not a data error.
Point Biopharma Global Inc's Competitive Forces (Porter's Five Forces)
Only the forces this data can support honestly are shown; the other three are marked as such rather than guessed.| Force | Assessment | Basis |
|---|---|---|
| Barriers to Entry | High (capital intensive) | Capital intensity (capex / revenue) of 7.93 % vs industry average 4.92 % (see Profitability & Cost Structure above) |
| Supplier Power | Not covered on this page | See Point Biopharma Global Inc's dedicated suppliers page for concentration and dependency data |
| Buyer Power | Not covered on this page | See Point Biopharma Global Inc's dedicated customers page for concentration and dependency data |
| Threat of Substitutes | - | No systematic data source for cross-product substitution exists in this system; not estimated |
Note: this is a partial, data-grounded application of the framework, not a complete strategic assessment. Rivalry and barriers-to-entry readings are mechanical translations of the HHI and capital-intensity figures shown elsewhere on this page, not independent judgments.
Point Biopharma Global Inc's Industry Attractiveness & Competitive Strength
A CSIMarket composite, not a standard field: each axis is an equal-weighted average of three factors already shown elsewhere on this page (industry growth, industry profitability and rivalry for attractiveness; relative market share, profitability and growth vs industry for strength). Disclosed as a designed methodology, not a precision measurement.
Point Biopharma Global Inc falls in the Low attractiveness / High strength cell: Selective.
Source: CSIMarket API, trailing 12 months. Each axis score is a simple 1(low)/2(medium)/3(high) average across its three inputs -- a transparent, disclosed simplification, not a validated academic scoring model.
Point Biopharma Global Inc's SWOT
Every point below is a fixed rule applied to a metric already shown elsewhere on this page (Market Structure, Profitability, Valuation, Run-Rate, Stock Performance, Quality Breadth) not an independent strategic assessment. A blank quadrant means no rule was met, not that none apply.Strengths
- Operating margin 152.1 points above the industry median.
- Return on equity 9.6 points above the industry aggregate.
Weaknesses
- Latest-quarter revenue run-rate is decelerating (-95.4% annualized vs trailing 12 months).
- Piotroski F-Score of 2 or below, the standard financial-distress signal.
Opportunities
- Trades at a lower P/E than the industry average (8.8x vs 25.1x) despite a higher return on invested capital -- a possible re-rating opportunity.
- A meaningful share of tracked competitors (53.70 %) show financial-distress signals, a possible opening to gain share.
Threats
- Tracked peer group's revenue run-rate is broadly decelerating (-98.9% annualized).
- High capital intensity requires continuous reinvestment just to keep pace with the industry.
Methodology: mechanical, rule-based SWOT. Each bullet reuses a figure already sourced and cited elsewhere on this page; nothing here is generated narrative or independent analyst judgment.
Point Biopharma Global Inc's Financial Strength vs Peers Comparison
Quick ratio, working capital, debt to equity and asset turnover, trailing 12 months| Company | Quick Ratio | Working Capital | Debt / Equity |
|---|---|---|---|
| Point Biopharma Global Inc | 2.01 | 7.38 | - |
| Novartis Ag | 0.42 | 1.12 | 0.02 |
| Roivant Sciences Ltd | 12.24 | 22.90 | - |
| Merus N v | 3.67 | 7.20 | - |
| Edgewise Therapeutics inc | 2.11 | 20.86 | - |
| Precigen Inc | 0.58 | 3.60 | 6.05 |
Sign in to see all peers for Point Biopharma Global Inc .
Quick ratio = cash / current liabilities; working capital ratio = current assets / current liabilities; asset turnover = revenue / total assets. Peers in the Blank Checks industry are excluded.
Point Biopharma Global Inc's Revenue and Income Growth vs Peers
Quarterly revenue and net income growth, year over year and quarter over quarter| Company | Period | Revenue Y/Y | Income Y/Y |
|---|---|---|---|
| Point Biopharma Global Inc | Q3 2023 | - | - |
| Novartis Ag | Q4 2025 | +9.6 % | +17.0 % |
| Roivant Sciences Ltd | Q2 2026 | -33.5 % | - |
| Merus N v | Q3 2025 | +3.2 % | - |
| Edgewise Therapeutics inc | Q2 2026 | - | - |
| Precigen Inc | Q1 2026 | +1,633.9 % | - |
| PEERS TOTAL | +9.5 % | +20.1 % |
Sign in to see all peers for Point Biopharma Global Inc .
Growth is shown only where both periods are positive. Peers in the Blank Checks industry are excluded.
Point Biopharma Global Inc's Peers' Costs of Sales and Capital Expenditures
Context for revenue growth: peer costs and capex, year over year and quarter over quarter| Company | Period | Costs Y/Y | Capex Y/Y |
|---|---|---|---|
| Point Biopharma Global Inc | Q3 2023 | - | -16.1 % |
| Novartis Ag | Q4 2025 | +18.3 % | +13.3 % |
| Roivant Sciences Ltd | Q2 2026 | - | -89.6 % |
| Merus N v | Q3 2025 | - | +21.0 % |
| Edgewise Therapeutics inc | Q2 2026 | - | - |
| Precigen Inc | Q1 2026 | +132.6 % | -58.5 % |
Sign in to see all peers for Point Biopharma Global Inc .
Point Biopharma Global Inc's Returns and Turnover vs Peers
ROA, ROI and ROE (trailing 12 months), receivables and inventory turnover| Company | ROA | ROI | ROE |
|---|---|---|---|
| Point Biopharma Global Inc | 18.28% | 20.60% | 21.10% |
| Novartis Ag | 12.59% | 12.62% | 30.00% |
| Roivant Sciences Ltd | - | - | - |
| Merus N v | - | - | - |
| Edgewise Therapeutics inc | - | - | - |
| Precigen Inc | - | - | - |
Sign in to see all peers for Point Biopharma Global Inc .
ROA = net income / total assets; ROI = net income / investments; ROE = net income / equity; turnover ratios use trailing 12 month revenue (receivables) and cost of sales (inventory).
Point Biopharma Global Inc's Valuation vs Peers
P/E, price to sales, PEG, price to cash flow and price to book| Company | P/E | Price / Sales |
|---|---|---|
| Point Biopharma Global Inc | 11.68 | 5.43 |
| Novartis Ag | 20.53 | 5.07 |
| Roivant Sciences Ltd | - | 3,538.81 |
| Merus N v | - | 120.32 |
| Edgewise Therapeutics inc | - | - |
| Precigen Inc | - | 87.58 |
| PEERS AVERAGE | 31.29 | 5.86 |
Sign in to see all peers for Point Biopharma Global Inc .
P/E = price / diluted EPS (trailing 12 months); PEG = P/E divided by EPS growth; the average row divides the peers' combined market cap by their combined income, sales, cash flow and equity.